S'abonner

Arsenic trioxide inhibits the functions of lung fibroblasts derived from patients with idiopathic pulmonary fibrosis - 09/03/22

Doi : 10.1016/j.rmr.2022.02.049 
A. Joannes 1, , C. Morzadec 1, F. Llamas Gutierrez 2, B. Richard De Latour 3, L. Wollin 4, S. Jouneau 1, 5, L. Vernhet 1
1 Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail)-UMR_S 1085, France 
2 Department of pathology and cytology, Rennes University Hospital, France 
3 Department of Thoracic, cardiac and vascular surgery, Rennes University Hospital, France 
4 Boehringer Ingelheim Pharma GmbH & Co, KG, Biberach an der Riss, Germany 
5 Department of Respiratory Diseases, Competence Center for Rare Pulmonary Disease, Rennes University Hospital, France 

Auteur correspondant.

Résumé

Introduction

Idiopathic pulmonary fibrosis (IPF) is a chronic and fatal interstitial lung disease. Actually, no treatment can block or reverse the development of lung fibrosis in patients suffering from IPF. The discovery of new antifibrosing drugs remains thus an area of intensive research. Arsenic trioxide (ATO), a safe and effective pro-oxidant drug used in cancer therapy, reduces in vivo experimental pulmonary fibrosis and prevents in vitro the differentiation of normal human lung fibroblasts (HLFs). In this context, the goal of this study was to determine if ATO could inhibit the main functions of HLFs isolated from patients with IPF.

Methods

IPF and non-IPF HLFs derived from lung biopsy isolated from patients with IPF or primary lung cancer. After pre-treatment with ATO (0.01–1μM) and stimulation with PDGF-BB (50ng/ml) or TGF-β1 (1ng/ml), proliferation, migration and differentiation of HLFs were assessed as well as the cell stress response.

Results

ATO did not affect cell viability but it significantly decreased, in a concentration-dependent manner, the proliferation and migration of control and IPF HLFs induced by PDGF-BB. The metalloid also prevented the myofibroblastic differentiation of HLFs determined by the expression of α-smooth muscle actin (α-SMA) and Collagen-1 proteins and the phosphorylation of SMAD2/3 in TGF-β1-stimulated HLFs. ATO effects were associated with stabilization of the transcription factor NRF2 and induction of the antioxidant proteins NQO1 and HO-1 that emphases the stress response developed by ATO-treated HLFs.

Conclusion

Our results demonstrate that ATO, in the range of arsenic plasmatic levels measured in patients treated with standard dosing of this drug, counteracted in vitro the detrimental functions of HLFs isolated from patients with IPF. ATO may thus be taken into consideration in the future as a new therapeutic option for IPF treatment.

Le texte complet de cet article est disponible en PDF.

Mot clé : Pathologies interstitielles


Plan


© 2022  Publié par Elsevier Masson SAS.
Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 39 - N° 2

P. 129 - février 2022 Retour au numéro
Article précédent Article précédent
  • Antifibrotics effects of nintedanib on lung fibroblasts derived from patients with progressive fibrosing intertitial lung diseases
  • A. Joannes, C. Morzadec, F. Llamas Gutierrez, B. Richard De Latour, L. Wollin, S. Jouneau, L. Vernhet
| Article suivant Article suivant
  • Le rôle de l’IgA et du pIgR dans la fibrose pulmonaire
  • T. Planté-Bordeneuve, C. Pilette, M. Lecocq, F. Huaux, A. Froidure

Déjà abonné à cette revue ?